Does chronic alcohol use by HIV-infected patients on d4T/3TC/NVP drug regimen effect the HIV viral load and what is the therapeutic window of the drugs, CD4+ count and WBC count in patients with high viral load during the 9 months period of follow up?

Godfrey S. Bbosa, William W. Anokbonggo, David B. Kyegombe, Muhammad Ntale, Apollo Mugisha, David Musoke, Jasper Ogwal-Okeng

Abstract


The study investigated the effects of chronic alcohol use on HIV viral load in HIV-infected patients on d4T/3TC/NVP drug regimen during 9 months follow up period. It also determined plasma drug concentrations of d4T, 3TC and NVP; CD4+ and WBC counts for patients with high HIV viral load. A case-control study using repeated measures with serial measurements was used. A total of 41 patients (20 alcohol group and 21 control group) were screened for alcohol use using WHO AUDIT tool and chronic alcohol use biomarkers. Blood sampling was done at 3 month intervals for a period of 9 months. HIV viral load was determined using Roche Amplicor HIV-1 monitor test, version 1.5 (Amplicor). The d4T, 3TC and NVP concentrations were determined by Shimadzu Class-VPTM HPLC Chromatography data system version 6.1. The CD4+ cell count was determined using FACSCalibur flow cytometer. The WBC was determined using automated hematological Coulter CBC-5 Hematology Analyzer system. Results show that % patients with HIV viral load ≥400 copies/ml in control group was highest (23.8%, n=5) at 3 month while in chronic alcohol use group, it was at 0 month (35%, n=7) for both WHO AUDIT tool and chronic alcohol-use biomarkers groups. Generally patients with high viral load ≥400 copies/ml was observed in chronic alcohol use as compared to control group in both WHO AUDIT tool and biomarkers group despite of patients having high steady state d4T, 3TC and NVP plasma drug concentrations in circulation that is available to suppress HIV virus. The high viral load could be associated with the emergence of resistance of the HIV virus and these patients generally had a low CD4+ cell count. Some of these patients had no detectable d4T plasma drug concentrations in circulation and most of them with high viral load had sub-therapeutic NVP plasma drug concentrations in their blood circulation. Chronic ethanol use by HIV-infected patients on d4T/3TC/NVP drug regimen increased HIV viral load and the patients with high viral load had sub-therapeutic NVP plasma drug concentrations and some with undetectable d4T drug concentrations in their blood circulation.


Keywords


Chronic alcohol use, Plasma, HIV viral load, d4T/3TC/NVP regimen

Full Text:

PDF

References


Butler IF, Pandrea I, Marx PA, Apetrei C. HIV genetic diversity: biological and public health consequences. Curr HIV Res. 2007 Jan;5(1):23-45.

UNAIDS, The global HIV challenge- assessing progress, identifying obstacles, renewing commitment 2008: Report on the global AIDS epidemic. Joint United Nations Programme on HIV/AIDS (UNAIDS) 2008. , 2008. 08: p. 14-362.

WHO/UNICEF/UNAIDS, Global HIV/AIDS Response: Epidemic update and health sector progress towards Universal Access, Progress Report 2011-2015. World Health Organization HIV/AIDS Department, Geneva, Switzerland. http://whqlibdoc.who.int/publications/2011/9789241502986_eng.pdf, 2011.

Lima, V.D., et al., Association between HIV-1 RNA Level and CD4 Cell Count Among Untreated HIV-Infected Individuals. Research and Practice. American Journal of Public Health. 2009. 99(S1): p. S193-S196.

Greene, W.C., et al., Novel Targets for HIV Therapy. Antiviral Research: Review. Elsevier Publishers., 2008. 80: p. 251-265.

GENACIS, Alcohol, Gender and Drinking Problems: Perspectives from Low and Middle Income Countries. Geneva, Switzerland. World Health Organization 2005., 2005: p. 2-241.

WHO, Global Status Report on Alcohol 2004. 2004: Geneva, Switzerland.

Kafuko, A. and P. Bukuluki, Qualitative research in Uganda on knowledge, attitude and practices concerning alcohol. 2008, USAID, Health Communication, YEAH and Afford: Corporate Agreement number 617-A-00-07-00005-00.

YEAH, Alcohol Consumption in Uganda: Literature Review. (Young Empowered and Health -YEAH) http://www.yeahuganda.org/research/AlcoholConsumption.pdf (Accessed on 22/07/09). 2007.

Kinoshita, H., et al., Acetaldehyde, a metabolite of ethanol activates the hypothalamic-pituitary-adrenal axis in the rat. Alcohol & Alcoholism, 2001. 36(1): p. 59-64.

Zakhari, S., Overview: How is alcohol metabolised by the body? The Journal of the National Institute on Alcohol Abuse and Alcoholism., 2006. 29(4): p. 245-252.

Edmunds-Obguokir, T., Understanding drug-drug interactions in the management of HIV disease:HIV Clinician. LSU—Delta Region AIDS Education & Training Center, New Orleans, LA, USA., 2002. 14(2): p. 1-4.

Fleming, M., S.J. Mihic, and R.A. Harris, Ethanol. Goodman Gilman’s, the pharmacological basis of therapeutics. McGraw-Hill Medical publishing Division, New York. 10th ed. 2001(18): p. 429-442.

SAMHSA, The role of Biomarkers in the treatment of alcohol use disorders. Substance Abuse and Mental Health Service Administration: US Center for substance abuse treatment. 2006. 5(4).

Whitfield, J.B., et al., Effects of Alcohol Consumption on Indices of Iron Stores and of Iron Stores on Alcohol Intake Markers. Alcohol Clinical Experimental Research. 2001;25(7):1037-45.

Edith, L., et al., Effect of alcohol consumption on blood antioxidant nutrients and oxidative stress indicators. American Journal of Clinical Nutrition 1994;60:255-261.

Figlie NB, et al. Biological Markers of Alcohol Consumption in Nondrinkers, Drinkers, and Alcohol-Dependent Brazilian Patients. WHO/ISBRA Study on State and Trait Markers of Alcohol Use and Dependence Investigators. Alcoholism: Clinical & Experimental Research 2002;26(7):1062-9.

Helander, A., B. Tabakoff, and WHO/ISBRA, Biochemical Markers of alcohol use and abuse:Experience from the pilot study of the WHO/ISBRA Collaborative Project on State and Trait Markers of alcohol. Alcohol & Alcoholism 1997;32(2):133-144.

Kovacs, E.J. and K.A.N. Messingham, Influence of Alcohol and Gender on Immune Response. National Institute on Alcohol Abuse and Alcoholism (NIAAA). 5635 Fishers Lane, MSC 9304, 2003: p. 1-13.

Chu, Y.C., Haematological Effects of Alcohol. Journal of the Hong Kong Medical Association, 1989. 41(1): p. 41-42.

Cook, R.T., Alcohol abuse, alcoholism, and damage to the immune system--a review. Alcoholism: Clinical Experimental Research, 1998. 22: p. 1927-1942.

Epstein, M., Alcohol’s Impact on Kidney Function. Alcohol Health and Research World, 1997. 21(1): p. 84-93.

Heringlake, M., et al., The effects of ethanol and vasopressin on renal function in the isolated perfused rat kidney. Applied Cardiopulmonary Pathophysiology, 2011. 15: p. 24-28.

Stein, D.M., et al., Adherence to Antiretroviral Therapy Among HIV-Infected Methadone Patients: Effect of Ongoing Illicit Drug Use. The American Journal of Drug and Alcohol Abuse. USA., 2000.

Webster, R.D. and D. Barr, Adherence to Highly Active Antiretroviral Therapy (HAART) Among Individuals with HIV/AIDS: A cmpendium of HAART Adherence Research, November 1997-November 1999. Washington D.C. USA. 1999: p. 1-13.

Broyles, B.M., Alcohol use, HIV infection and antiretroviral adherence. PhD Reseach Dissertation. School of Nursing, University of Pittsburgh. , 2008: p. 1-27.

IMPACT, Counterfeit drugs kill. International Medical Products Anti-Counterfeiting Taskforce (IMPACT). World Health Organisation Drug Information, 2006. www.who.int/impact.

Gautam, C.S., A. Utreja, and G.L. Singal, Singal, Spurious and counterfeit drugs: a growing industry in the developing world Postgraduate Medical Journal, 2009. 86: p. 251-256. http://pmj.bmj.com/ cgi/reprint/85/1003/251.pdf.

Calcagno A, et al. Is peritoneal fluid a sanctuary site for HIV? Journal of Antimicrobial Chemotherapy, 2010;65(9):2052-2053.

Choudhary, S.K. and D.M. Margolis, Curing HIV: Pharmacologic Approaches to Target HIV-1 Latency. Annual Review of Pharmacology and Toxicology 2011;51:397-418.

Babor TF, et al. The Alcohol Use Disorders Identification Test (AUDIT) Manual: Guidelines for Use in Primary Care. Second Edition. Department of Mental Health and Substance Dependence. World Health Organization 2001. WHO/MSD/MSB/01.6a., 2001: p. 4-32.

Pyne, M.T., K.L. Brown, and D.R. Hillyard, Evaluation of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Test and Identification of Rare Polymorphisms Potentially Affecting Assay Performance. Journal of Clinical Microbiology, 2010. 48(8): p. 2852.DOI:10.1128/JCM.00776-10.http://jcm.asm.org/content/48/8/2852.full.pdf.

Roche, COBAS AmpliScreen HIV-1 Test, version 1.5. Roche Diagnostics GmbH, 2006: p. http://www.roche-diagnostics.cz/download/mol/transfuzni/Cobas_AmpliScreen_HIV-1_test_v1.5.pdf.

Notari, S., et al., Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography. Journal of Chromatography B, 2006. 831: p. 258-266.

Mbopi-Kéou, F.-X., et al., Validation of a single-platform, volumetric, flow cytometry for CD4 T cell count monitoring in therapeutic mobile unit. Journal of Translational Medicine, 2012. 10(22): p. http://www.translational-medicine.com/content/pdf/1479-5876-10-22.pdf.

Nantakomol, D., et al., Affordable Technology for Enumeration of the Absolute CD4 T-Lymphocyte Count by Cell Bead Assay. Scince: Lab Medicine, 2010. 41(7): p. 423-428. http://labmed.ascpjournals. org/content/41/7/423.full.pdf.

Jean-claude, R., Alcohol, Wine and Platelet Function. Biological Research., 2004. 37: p. 209-215.

Oduola, T., et al., Drinking patterns: biochemical and haematological findings in alcohol consumers in IIe-Ife, Nigeria. African Journal of Biotechnology., 2005. 4(11): p. 1304-1308.

Bartlett, J.G. and J.E. Gallant, Medical Management of HIV Infection. Johns Hopkins University School of Medicine. Johns Hopkins Medicine Health Publishing Business Group. Baltimore, USA.2005-2006. , 2006.

Dobrinas, M. and C.B. Eap, Cytochrome P4503A pharmacogenetics. HIV PGX 2:2, 2007., 2007: p. 1-3.

Fellay, J., et al., Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. European Journal of Clinical Pharmacology 2005(60): p. 865–873.

Faragon, J.J. and P.J. Piliero, Drug Interactions Associated With HAART: Focus on Treatments for Addiction and Recreational Drugs. Cliggott Publishing, Division of SCP Communications, AIDS Reader, 2003. 13(9): p. 433-450.

Triplit, C., Drug Interactions of Medications Commonly Used in Diabetes. Diabetes Spectrum, 2006. 19(4): p. 202-211.

Conradie, F., The 2012 southern African ARV drug resistance testing guidelines: Guidelines. South African Journal of HIV Medicine, 2012. 13(4): p. 162-167. DOI:10.7196/SAJHIVMED.874. http://www.sahivsoc.org/upload/documents/The%202012%20southern%20African%20ARV%20drug%20resistance%20testing%20guidelines.pdf.

Rossi, L., HIV Drug Resistance and ARV-Based Prevention. Microbicide Trials Network (MTN), 2010: p. http://www.mtnstopshiv.org/sites/default/files/attachments/resistanceQandA9-27-10.pdf.

WHO/IAS, HIV Drug Resistance Surveillance Network: WHO and International AIDS Society Building. WHO and International AIDS Society, 2013: p. http://www.who.int/drugresistance/ hivaids/en/HIVdrugnetwork.pdf.

Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002 Apr 15;34(8):1115-21.

Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001 Oct 15;33(8):1417-23.